

2-2021

Use of active comparator trials in dermatology: A repeated cross-sectional analysis

John Miller

Thomas Jefferson University, john.miller@students.jefferson.edu

John Barbieri, MD

Arash Mostaghimi, MD

Sophia Ly

Follow this and additional works at: https://jdc.jefferson.edu/si_hs_2023_phase1

 Part of the [Dermatology Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Miller, John; Barbieri, MD, John; Mostaghimi, MD, Arash; and Ly, Sophia, "Use of active comparator trials in dermatology: A repeated cross-sectional analysis" (2021). *Phase 1*. Paper 5.


https://jdc.jefferson.edu/si_hs_2023_phase1/5

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Use of active comparator trials in dermatology: A repeated cross-sectional analysis

John Miller, Sophia Ly, Arash Mostaghimi MD, John Barbieri MD*

Introduction: Healthcare Spending Costs



Aitken M, Kleinrock M. *Medicine Use and Spending in the U.S.* IQVIA Institute for Human Data Science; 2019. Accessed November 3, 2019.

- Overall out-of-pocket costs have risen to \$61 billion in 2018

Healthcare spending impact on patients?

Spending on prescription medications is expected to rise to \$420 billion by 2023.²



Nearly 30% of patients reported not taking prescription due to cost.



shutterstock.com • 1450576703

The Role of Active Comparator Clinical Trials

Placebo Controlled



vs.



Active Comparator



vs.



While placebo-controlled trials are valuable to understand efficacy, active comparator trial designs provide data that can guide clinical decision making by allowing direct comparisons between similar drugs

Active Comparators in Dermatology Topical Trials

In dermatology, subtle changes in concentration or combination of topical agents can be classified as a novel product.

While some new medications may improve patient outcomes, others may not offer meaningful benefit over existing less costly alternatives.



0.1%



0.3%

The Inquiry Question:

To evaluate trends in the use of active comparator trial designs for topical medications approved by the FDA between January 2002 and December 2020.

Methods

- Population

- Food and Drug Administration
- Physicians
- Patients



- Resources Used

- Clinical Trials Database
 - Clinical Trial Information
- FDA Orange Book
 - Drug Approval Dates




Outcomes & Analysis

- Outcomes

- Frequency of Active Comparator over Time
- Frequency of Active Comparator by Trial Phase


- Analysis

- Linear Regression



Outcomes

- Between 2002 and 2020, the proportion of clinical trials for acne, psoriasis, and eczema with an active comparator has decreased. (-5.2% per year, 95% CI -1.7% to -8.6%)



Outcomes

- Phase II studies were most likely to include and active comparator (71%), while phase III studies were least likely (32%).

% Trials with and Active Comparator by Clinical Indication				
	<i>Phase II</i>	<i>Phase III</i>	<i>Phase IV</i>	Total
Psoriasis	83% n=6	39% n=28	29% n=7	44% n=41
Acne	100% n=1	35% n=23	71% n=14	50% n=38
Actinic Keratosis	75% n=4	23% n=13	80% n=5	45% n=22
Antifungal	67% n=6	15% n=13	0% n=1	30% n=20
Rosacea	0% n=2	43% n=7	0% n=1	30% n=10
Eczema	50% n=2	0% n=2	0% n=1	20% n=5
Other	77% n=13	35% n=23	0% n=5	44% n=41
Total	71% n=34	32% n=109	47% n=34	42% n=117

Conclusions

- Although there is a greater need for comparative effectiveness data in the setting of a growing number of available treatments, our results highlight that the use of active comparator trials has decreased over time



Moving Forward (Impact):

- It will be important for clinicians, patients, payers, and

Role of Patient Reported Outcomes

Absolute Lesion Reduction vs. Quality of Life Index

- COST-BENEFITS ANALYSES
- FDA Regulated Guidelines



Disclosures and Acknowledgements

- Huge thanks to Dr. Barbieri for his mentorship, Dr. Mostaghimi for his insightful critiques, and Sophia Ly for scouring the clinical trials database for hours upon hours.

Citations

- Aitken M, Kleinrock M. *Medicine Use and Spending in the U.S.* IQVIA Institute for Human Data Science; 2019. Accessed November 3, 2019.
- Kirzinger A. KFF Health Tracking Poll - February 2019: Prescription Drugs. *Medical Benefits*. 2019;36(6):4-5. Accessed January 19, 2021.
- Barbieri JS, Tan JKL, Adamson AS Active Comparator Trial Designs Used to Promote Development of Innovative New Medications. *Cutis*. 2020 Sep;106(3):E4-E6
- Olfson M, Marcus SC. Decline in placebo-controlled trial results suggests new directions for comparative effectiveness research. *Health Aff Proj Hope*. 2019;32 116-1122
- Drugs for Human Use Subchapter D, 21 C.F.R. § 300.50 (2020).



Jefferson

**Philadelphia University +
Thomas Jefferson University**

HOME OF SIDNEY KIMMEL MEDICAL COLLEGE